Aspirin for Primary Prevention of Coronary Events
- 9 May 2002
- journal article
- case report
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 346 (19) , 1468-1474
- https://doi.org/10.1056/nejmcp012672
Abstract
A 45-year-old man with a strong family history of premature heart disease has no symptoms of coronary disease and a normal electrocardiogram. His fasting level of total cholesterol is 225 mg per deciliter, the low-density lipoprotein cholesterol level is 160 mg per deciliter, and the high-density lipoprotein cholesterol level is 35 mg per deciliter. He has no history of hypertension and does not smoke cigarettes. Should he be advised to take aspirin to reduce his risk of myocardial infarction?Keywords
This publication has 47 references indexed in Scilit:
- Validation of the Framingham Coronary Heart Disease Prediction ScoresJAMA, 2001
- Updated guidelines for cholesterol management.JAMA, 2001
- Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trialsHeart, 2001
- Guide to Primary Prevention of Cardiovascular DiseasesCirculation, 1997
- Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenNew England Journal of Medicine, 1997
- The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatmentPublished by American Medical Association (AMA) ,1997
- Inflammation and Coronary Artery DiseaseNew England Journal of Medicine, 1994
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- Final Report on the Aspirin Component of the Ongoing Physicians' Health StudyNew England Journal of Medicine, 1989
- Effect of alternate-day regular and enteric-coated aspirin on platelet aggregation, bleeding time, and thromboxane A2 levels in bleeding-time bloodThe American Journal of Medicine, 1986